Registration Application of Azvudine Tablets for the Treatment of COVID-19 Has Been Approved

On Jul. 25, Henan Genuine Biotech Co., Ltd. (hereinafter referred to as "Genuine Biotech") announced that the registration application of small-molecule oral drug Azvudine tablets, independently developed by the company for the treatment of COVID-19, has been granted conditional approval by the National Medical Products Administration.

Dr. Du Jinfa, CEO and CSO of Genuine Biotech, said, "This is the first domestic oral drug for COVID-19 approved for marketing in China, and we hope that Azvudine tablets will powerfully contribute to the fight against the COVID-19 pandemic."

Wang Chaoyang, founder of Genuine Biotech, said, "We are very pleased to hear this good news and are looking forward that Azvudine tablets will help to fight against the pandemic and ensure the normalcy of social and economic life. Since the company was founded 10 years ago, Genuine Biotech has always adhered to a realistic and pragmatic approach in scientific research, taken the responsibility to improve human health, to provide safer and more efficient treatment options for unmet clinical needs.”